摘要
基因导向性酶前体药物疗法(GDEPT)包括将负责原位转化前体药物成为细胞毒性代谢物的自杀基因靶向投递到肿瘤细胞中,这种方法应用到临床的主要限制是自杀基因的前药活化能力差。我们通过融合CYP2B6三突变体与NADPH细胞色素P450还原酶( CYP2B6TM -RED ),建立了一个能高效生物激活前体药物环磷酰胺(CPA)的自杀基因。这种融合基因的表达通过重组慢病毒(LV)载体转化抗人( A549 )和鼠( TC1 )肺细胞系进入CPA敏感的细胞系。我们在C57Bl/6免疫小鼠身上测试了我们的基因导向性酶前体药物治疗的效力,使用能够表达HPV-16 E6 / E7癌蛋白的TC1细胞。在仅由 TC1-CYP2B6TM-RED细胞构成的小鼠肿瘤上注射4次环磷酰胺后(140毫克/公斤,每周一次)能在两个月后完全根除肿瘤。含有25%TC1-CYP2B6TM-RED细胞构成的肿瘤也能在注射5次环磷酰胺后根除,展现了主要的体内旁观者效应。而且,存活的小鼠都被再次采用亲代TC1细胞进行测试。肿瘤在细胞接种后七日自然消退或是增长慢于对照组的未给药幼鼠,这是由于受到抗E7CD8 + T细胞介导的强烈的免疫反应。这些数据表明CYPB6TM -RED基因与CPA联合有望成为一种能非常有效治疗人类实体瘤的治疗手段。
关键词: 细胞色素P450 2B6,慢病毒,环磷酰胺,肺
Current Gene Therapy
Title:A Suicide Gene Therapy Combining the Improvement of Cyclophosphamide Tumor Cytotoxicity and the Development of an Anti-Tumor Immune Response
Volume: 14 Issue: 3
Author(s): Walid Touati, Thi Tran, Johanne Seguin, Monique Diry, Jean-Pierre Flinois, Claude Baillou, Geraldine Lescaille, Francois Andre, Eric Tartour, Francois M. Lemoine, Philippe Beaune and Isabelle de Waziers
Affiliation:
关键词: 细胞色素P450 2B6,慢病毒,环磷酰胺,肺
摘要: Gene-directed enzyme prodrug therapy (GDEPT) consists in targeted delivery to tumor cells of a suicide gene responsible for in situ conversion of a prodrug into cytotoxic metabolites. One of the major limitations of this strategy in clinical application was the poor prodrug activation capacity of suicide gene. We built a highly efficient suicide gene capable of bioactivating the prodrug cyclophosphamide (CPA) by fusing a CYP2B6 triple mutant with NADPH cytochrome P450 reductase (CYP2B6TM-RED). Expression of this fusion gene via a recombinant lentivirus (LV) vector converted resistant human (A549) and murine (TC1) pulmonary cell lines into CPA-susceptible cell lines. We tested the efficiency of our GDEPT strategy in C57Bl/6 immunocompetent mice, using TC1 cells expressing the HPV-16 E6/E7 oncoproteins. In mice bearing tumors composed only of TC1-CYP2B6TM-RED cells, four CPA injections (140 mg/Kg once a week) completely eradicated the tumors for more than two months. Tumors having only 25% of TC1-CYP2B6TM-RED cells were also completely eradicated by five CPA injections, demonstrating a major in vivo bystander effect. Moreover, surviving mice were rechallenged with parental TC1 cells. The tumors regressed spontaneously 7 days after cell inoculation or grew more slowly than in control naive mice due to a strong immune response mediated by anti-E7CD8+T cells. These data suggest that combining the CYPB6TM-RED gene with CPA may hold promise as a highly effective treatment for solid tumors in humans.
Export Options
About this article
Cite this article as:
Touati Walid, Tran Thi, Seguin Johanne, Diry Monique, Flinois Jean-Pierre, Baillou Claude, Lescaille Geraldine, Andre Francois, Tartour Eric, Lemoine M. Francois, Beaune Philippe and de Waziers Isabelle, A Suicide Gene Therapy Combining the Improvement of Cyclophosphamide Tumor Cytotoxicity and the Development of an Anti-Tumor Immune Response, Current Gene Therapy 2014; 14 (3) . https://dx.doi.org/10.2174/1566523214666140424152734
DOI https://dx.doi.org/10.2174/1566523214666140424152734 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Circumventing Immune Tolerance Through Epigenetic Modification
Current Pharmaceutical Design Synthesis of 99mTc-Nimotuzumab with Tricarbonyl Ion: in vitro and in vivo Studies
Current Radiopharmaceuticals The Role of Ghrelin Signals in Breast Cancer- A Systematic Review
Current Signal Transduction Therapy Oncogenic MicroRNA-27a is a Target for Genistein in Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Anti-Cancer Properties of Nigella spp. Essential Oils and their Major Constituents, Thymoquinone and β-Elemene
Current Clinical Pharmacology Anti-Cancer/Anti-Tumor
Current Bioactive Compounds Discovery of Selective Probes and Antagonists for G Protein-Coupled Receptors FPR/FPRL1 and GPR30
Current Topics in Medicinal Chemistry The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery Calcium Ion – The Key Player in Cerebral Ischemia
Current Medicinal Chemistry Editorial [Hot Topic: Immunotherapy of Cancer (Guest Editors: Ezra E.W. Cohen and Nikolai G. Rainov)]
Reviews on Recent Clinical Trials Transmembrane Phosphatases and Cancer Development, the Role of Protein Tyrosine Phosphatase-kappa (PTPκ) and Protein Tyrosine Phosphatase-mu (PTPμ)
Current Signal Transduction Therapy Apoptotic Signaling in Pancreatic Cancer – Therapeutic Application (Supplemental Data)
Current Cancer Therapy Reviews Nanoparticle-Based Tumor Theranostics with Molecular Imaging
Current Pharmaceutical Biotechnology Improvement of Tumor Localization of Photosensitizers for Photodynamic Therapy and Its Application for Tumor Diagnosis
Current Topics in Medicinal Chemistry Exploiting Cyclooxygenase-(in)Dependent Properties of COX-2 Inhibitors for Malignant Glioma Therapy
Anti-Cancer Agents in Medicinal Chemistry Histone Methyltransferase Inhibitors: Novel Epigenetic Agents for Cancer Treatment
Current Medicinal Chemistry Recent Progress in the Syntheses and Biological Evaluation of Boronated Porphyrins for Boron Neutron-Capture Therapy
Anti-Cancer Agents in Medicinal Chemistry Differentiation of High-grade Gliomas from Brain Metastases Using Tissue Similarity Maps (TSMs) Based Relative Cerebral Blood Volume Values
Current Medical Imaging Recognition Sites for Cancer-targeting Drug Delivery Systems
Current Drug Metabolism Ion Transporters in Brain Tumors
Current Medicinal Chemistry